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Abstract
Background: The mechanisms by which macrophage phenotype contributes to mesenchymal stem cells (MSC)-
mediated bone repair remain unclear. In this work, we investigated the influence of factors released by human
macrophages polarized to a pro-inflammatory or an anti-inflammatory phenotype on the ability of human MSC to
attach, migrate, and differentiate toward the osteoblastic lineage. We focused on the role of TNF-α and IL-10, key
pro-inflammatory and anti-inflammatory cytokines, respectively, in regulating MSC functions.
Methods: MSC were treated with media conditioned by pro-inflammatory or anti-inflammatory macrophages to
study their influence in cell attachment, migration, and osteogenic differentiation. The involvement of TNF-α and IL-
10 in the regulation of MSC functions was investigated using neutralizing antibodies and recombinant cytokines.
Results: Treatment of MSC with media conditioned by pro-inflammatory or anti-inflammatory macrophages
promoted cell elongation and enhanced MSC ability to attach and migrate. These effects were more noticeable
when MSC were treated with media from pro-inflammatory macrophages. Interestingly, MSC osteogenic activity
was enhanced by factors released by anti-inflammatory macrophages, but not by pro-inflammatory macrophages.
Significant IL-10 levels originated from anti-inflammatory macrophages enhanced MSC osteogenesis by increasing
ALP activity and mineralization in MSC layers cultured under osteogenic conditions. Moreover, macrophage-derived
IL-10 regulated the expression of the osteogenic markers RUNX2, COL1A1, and ALPL. Notably, low TNF-α levels
secreted by anti-inflammatory macrophages increased ALP activity in differentiating MSC whereas high TNF-α levels
produced by pro-inflammatory macrophages had no effects on osteogenesis. Experiments in which MSC were
treated with cytokines revealed that IL-10 was more effective in promoting matrix maturation and mineralization
than TNF-α.
Conclusions: Factors secreted by pro-inflammatory macrophages substantially increased MSC attachment and
migration whereas those released by anti-inflammatory macrophages enhanced MSC osteogenic activity as well as
cell migration. IL-10 was identified as an important cytokine secreted by anti-inflammatory macrophages that
potentiates MSC osteogenesis. Our findings provide novel insights into how environments provided by
macrophages regulate MSC osteogenesis, which may be helpful to develop strategies to enhance bone
regeneration.
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Introduction
Inflammatory response mediated by macrophages plays a
vital role in fracture healing [1, 2]. Upon bone injury,
monocytes are recruited to the wound site and differentiate
into activated macrophages, a major source of cytokines in-
volved in bone repair and regeneration. Macrophage popu-
lations can adopt differential functional profiles ranging
from the pro-inflammatory polarization state M1 to the
anti-inflammatory M2. In the initial phase of inflammation,
M1-type macrophages secrete high amounts of pro-
inflammatory cytokines such as tumor necrosis factor-
alpha (TNF-α). TNF-α, a primary mediator in the
inflammatory reaction, promotes the recruitment of inflam-
matory and stromal cells, stimulates angiogenesis and is es-
sential for bone fracture repair, as demonstrated in TNF-α
receptor-deficient mice [3, 4]. In the later stages of inflam-
mation, M2-type macrophages secrete anti-inflammatory cy-
tokines and growth factors, which mediate the resolution of
inflammation and tissue repair. Among them, interleukin-10
(IL-10) is a key anti-inflammatory cytokine in the bone re-
generative process. IL-10-deficient mice display osteopenia,
mechanical fragility of bones, and decreased bone formation
[5]. The outcome of bone repair is tightly regulated by the
inflammatory milieu, leading the imbalance between pro-
inflammatory and anti-inflammatory cytokines during bone
healing to chronic inflammation, aberrant bone repair, or ex-
cessive ossification.
The early step of bone formation involves the migration
of mesenchymal stem cells (MSC), which undergo prolif-
eration and differentiation along the osteoblastic lineage.
Indeed, MSC implantation has emerged as a promising
strategy for promoting bone regeneration in several clin-
ical conditions, including delayed unions and non-unions,
critical-sized bone defects, periprosthetic osteolysis, osteo-
necrosis, and inflammatory bone disorders [6–10]. The
benefits of MSC therapy are mainly attributed to paracrine
effects via soluble factors, exerting both immunoregula-
tory and regenerative actions [11]. Although implanted
MSC may act as osteoprogenitors [12–14], most evidence
indicates that newly formed bone is mainly derived from
host progenitors. The mechanisms by which macrophages
contribute to MSC-mediated tissue repair remain unclear.
TNF-α, which is highly expressed in macrophages during
the early inflammatory phase after fracture [15], promotes
MSC migration and plays an important role in the activa-
tion of MSC immunoregulatory properties [16–18]. More-
over, pro-inflammatory cytokines can directly impact
MSC commitment to the osteoblastic lineage. Thus, TNF-
α contained in supernatants from human fractured tibial
bone enhances MSC osteogenic differentiation in vitro
[19]. Further studies using recombinant TNF-α show that
its effect on MSC osteogenesis depends on the dose and
the length of treatment [19–23]. Regarding anti-
inflammatory cytokines, their effects on bone healing have
been largely explained by their ability to inhibit the pro-
duction of pro-inflammatory factors by macrophages [24].
However, very little attention has focused on their direct
effects on MSC. We recently reported that IL-10 origi-
nated from pro-resolving macrophages enhances MSC
immunomodulatory potential in vitro [18]. In addition, a
recent study showed that physiological doses of recombin-
ant IL-10 stimulate MSC osteogenic differentiation while
higher pathological doses inhibit it [25].
In the present study, we investigated the influence of fac-
tors produced by human macrophages polarized to a pro-
inflammatory or an anti-inflammatory phenotype on the
ability of MSC to attach, migrate, and differentiate toward
the osteoblastic lineage. We focused on the role of TNF-α
and IL-10, key pro-inflammatory and anti-inflammatory cy-
tokines, respectively, in regulating MSC functions.
Methods
Isolation and culture of primary human macrophages
Buffy coats were obtained from 15 healthy blood donors
anonymously provided by the Comunidad de Madrid
Blood Bank (Madrid, Spain). This study was approved by
the Human Research Committee of Hospital Universitario
La Paz (date of approval 03/06/2015). All experiments
were carried out in accordance with the approved guide-
lines and regulations. Human peripheral blood mono-
nuclear cells (PBMC) were isolated from buffy coats by
Ficoll-Paque Plus (GE Healthcare Bio-sciences, Uppsala,
Sweden) density gradient centrifugation. PBMC were
seeded at a density of 15 × 106/well in 6-well plates and
allowed to adhere for 1 h in serum-free RPMI (Lonza, Ba-
sel, Switzerland). Attached cells were incubated for 7 days
in RPMI supplemented with 10% (v/v) heat-inactivated
fetal bovine serum (FBS) and 200 U/ml granulocyte
macrophage colony-stimulating factor (GM-CSF) or 20
ng/ml macrophage colony-stimulating factor (M-CSF)
(both from Peprotech, London, UK). Cytokines were
added every 2 days. Macrophages generated after incuba-
tion with GM-CSF (MΦGM) expressed the M1 markers
CD80 and CCR7 while they were devoid of the cell-
surface receptor CD163, a marker of M2 macrophages. In
contrast, macrophages generated after incubation with M-
CSF (MΦM) expressed high levels of CD163 and very low
levels of CD80 and CCR7 [18]. Conditioned medium
(CM) was obtained from MΦGM and MΦM treated
(CMGM+ and CMM+, respectively) or not (CMGM- and
CMM-, respectively) with 10 ng/ml lipopolysaccharide
(LPS) (Sigma, Madrid, Spain) for 90min, washed three
times with phosphate-buffered saline (PBS) and cultured
for 5 h in RPMI supplemented with 10% FBS in the ab-
sence of LPS. The experimental scheme used to generate
CM is shown in Fig. 1a. CM was clarified by centrifugation
at 1200 g for 10min. Levels of TNF-α, IL-6, IL-1β, IL-10,
IL-8, and monocyte chemoattractant protein-1 (MCP-1)
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Fig. 1 Morphology of MSC treated with CM. a Experimental scheme used for generating conditioned medium (CM) from macrophages and for
MSC treatments. CMGM+ and CMM+ were obtained from MΦGM and MΦM, respectively, that were treated with LPS for 90 min, thoroughly washed
with PBS, and further incubated in fresh medium for 5 h. CMGM− and CMM− were obtained from MΦGM and MΦM, respectively, that were not
treated with LPS but subjected to identical experimental manipulations. MSC were incubated or not with CM for 48 h, thoroughly washed with
PBS, and further incubated in growth (GrM) or osteogenic (OM) medium up to 21 days. b Optical microscope images showing the morphology
of MSC treated or not (−) with CM after crystal violet staining (upper row). Confocal microscope images (maximum projection) showing actin
(red) and nuclei (blue) in MSC treated or not with CM (lower row). c Ratio of cell length to width as measure of cell elongation. *p < 0.05
between the indicated conditions
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in CM were determined using BD CBA Flex Sets (BD Bio-
sciences, San Jose, CA, USA). The data were acquired
using a FACSCalibur flow cytometer and analyzed with
the FCAP Array Software version 3.0 (BD Biosciences).
The detection limits were 3.7 pg/ml for TNF-α, 2.5 pg/ml
for IL-6, 2.6 pg/ml for IL-1β, 3.3 pg/ml for IL-10, 1.2 pg/
ml for IL-8, and 1.3 pg/ml for MCP-1.
MSC culture and treatments
Human MSC derived from bone marrow were purchased
from Lonza and expanded in a defined growth medium
consisting of basal medium and supplements (Lonza). All
experiments were performed below the seventh cell pas-
sage. Experiments were performed in duplicate using
MSC isolated from five different donors aged 18–31 years.
MSC were incubated for 48 h in DMEM supplemented
with 15% (v/v) heat-inactivated FBS (growth medium) or
in a mixture of equal volumes of growth medium and
CM. When indicated, and prior to addition to MSC, CM
was incubated for 1 h at 37 °C with 1 μg/ml neutralizing
antibody against TNF-α or IL-10 (Biolegend, San Diego,
CA, USA). In some experiments, MSC were incubated in
growth medium containing human TNF-α or IL-10 at 0.1,
1, or 10 ng/ml (Peprotech). This concentration range was
selected according to TNF-α and IL-10 levels in CMGM+
or CMM+. In differentiation assays, MSC treated with CM
or cytokines were washed three times with PBS and incu-
bated in osteogenic medium consisting of growth medium
supplemented with 3 × 10−4M ascorbic acid, 10−2M β-
glycerophosphate, and 10−7M of dexamethasone (all from
Sigma) for 3–21 days. As controls, untreated cells were in-
cubated in the growth medium. The experimental scheme
is shown in Fig. 1a.
Cell morphology, attachment, and migration
To analyze cell morphology, 2 × 104 MSC were seeded in
8-well chamber slides and incubated for 48 h in 200 μl of a
mixture of equal volumes of growth medium and CM or
in 200 μl of growth medium supplemented or not with the
indicated cytokines. Cells were washed with PBS, stained
with crystal violet, and observed under a phase-contrast
microscope (Nikon Diaphot, Tokio, Japan). Cell elong-
ation was determined by analyzing a total of 100 cells per
condition, randomly selected from 6 representative images
obtained from 3 independent experiments with similar re-
sults. Cells were manually outlined using ImageJ v1.34
image analysis software (http://rsbweb.nih.gov/ij), which
fits each cell to the fittest ellipse. The lengths of the major
and the minor axis of the fittest ellipse correspond to cell
length and width, respectively. Elongation was defined as
the ratio of the major axis to the minor axis. Parallel sets
of cells were fixed with 4% (w/v) formaldehyde in PBS,
permeabilized with 0.1% Triton X-100 in PBS and double-
stained with PBS containing 4 × 10−7M phalloidine-
tetramethylrhodamine (TRITC) (Sigma) and 3 × 10−6M 4,
6-diamidino-2-phenylindole (DAPI, Sigma). Images of
fluorescently stained cells were obtained using a Leica
TCS SPE confocal microscope (Wetzlar, Germany).
For cell attachment assays, 106 MSC were seeded in
100 mm diameter culture dishes and incubated for 48 h
in 10 ml of a mixture of equal volumes of growth
medium and CM or in 10 ml of growth medium supple-
mented or not with the indicated cytokines. Cells were
detached and seeded at a density of 105/well in 24-well
plates for 0.5, 1, 2, or 3 h in growth medium. After wash-
ing extensively with PBS, attached cells were trypsinized
and the number of live cells at each time point was
quantified by the trypan blue dye exclusion method. To
determine cell migration, 2 × 104 MSC were seeded on
tissue culture plastic surfaces confined within squared
silicone barriers (Flexiperm, Sigma) placed in 6-well
plates and incubated for 48 h in 200 μl of a mixture of
equal volumes of growth medium and CM or in 200 μl
of growth medium. After washing three times with PBS,
the silicon barrier was removed, allowing cells to mi-
grate, and cultures were incubated for 5 days in growth
medium. Cells were subsequently stained with crystal
violet and observed under a phase-contrast microscope.
In some experiments, MSC were incubated in growth
medium supplemented with human TNF-α or IL-10 at
1 ng/ml or with IL-10 at 10 ng/ml and cell attachment
and migration were determined as described above.
Cell viability
105 MSC were seeded in 12-well plates and incubated
for 48 h in 1 ml of a mixture of equal volumes of growth
medium and CM or in 1 ml of growth medium supple-
mented or not with the indicated cytokines. After wash-
ing three times with PBS, MSC were incubated for 1, 3,
and 7 days in growth medium. Cell viability was deter-
mined using the alamarBlue assay (Biosource, Nivelles,
Belgium). Briefly, MSC were incubated in DMEM con-
taining 10% alamarBlue dye for 3 h and the fluorescence
emitted by cell-reduced alamarBlue was quantified using
a spectrofluorimeter (Synergy4, Evry, France).
ALP activity and cell layer calcification assays
2 × 105 MSC were seeded in 6-well plates and incubated
for 48 h in 2ml of a mixture of equal volumes of growth
medium and CM or in 2ml of growth medium supple-
mented or not with the indicated cytokines. After washing
with PBS, MSC were induced to undergo differentiation
by incubation in osteogenic medium up to 21 days. As
controls, untreated cells were incubated in growth
medium. Media were partially replaced every 3 days. After
14 days of culture, cell layers were extracted with 5 × 10−1
M NaCl, 5 × 10−2M Tris-HCl pH 8.0, and 1% Triton X-
100 and supplemented with a mixture of protease
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inhibitors. Alkaline phosphatase (ALP) activity was
assessed in cell layers by determining the release of p-
nitrophenol from p-nitrophenyl phosphate (Sigma). The
data were normalized to the total protein contents deter-
mined by a Bradford-based protein assay (Bio-Rad Labora-
tories Inc., Hercules, CA). The degree of cell layer
calcification was assessed in cells cultured for 3–21 days
using alizarin red staining. Briefly, cells were fixed with etha-
nol and stained with 40mM alizarin red S in deionized water
at pH 4.2. Images of stained cell layers were obtained using a
phase-contrast microscope. The bound stain was eluted with
10% (w/v) cetylpyridinium chloride and the absorbance at
562 nm was measured using a spectrofluorometer.
Gene expression
2 × 105 MSC were seeded on 6-well plates and incubated for
48 h in 2ml of a mixture of equal volumes of growth
medium and CM or in 2ml of growth medium supple-
mented or not with the indicated cytokines. MSC were har-
vested immediately after treatment with CM or cytokines or
after washing with PBS and further incubation in osteogenic
medium for 3–21 days. Total RNA was isolated using TRI
Reagent (Molecular Research Center, Inc., Cincinnati, OH,
USA). Complementary DNAs were prepared from total
RNA using the Transcriptor Reverse Transcriptase and an
anchored-oligo (dT)18 primer (Roche Applied Science, In-
dianapolis, IN, USA). Real-time quantitative PCR was per-
formed using the LightCycler FastStart DNA Master SYBR
Green I and a LightCycler instrument (Roche). Quantitative
expression values were extrapolated from standard curves
and normalized to the expression values of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Due to a lack of stabil-
ity of GAPDH expression in cells incubated under osteogenic
conditions, quantitative expression values from cells cultured
in osteogenic medium were normalized to the mean of the
expression values of hypoxanthine-guanine phosphoribosyl-
transferase (HPRT1) and beta-glucuronidase (GUSB). Spe-
cific oligonucleotide primers were runt-related transcription
factor 2 (RUNX2), 5′-ATGATGACACTGCCACCTCTGA-
3′ (forward primer, F), 5′-GGCTGGATAGTGCATTCG
TG-3′, (reverse primer, R); collagen type I alpha 1 (COL1A1),
5′-CGGGCCTCAAGGTATTGCT-3′ (F) and 5′-GGGACC
TTGTTTGCCAGGTT-3′ (R); ALPL, 5′- GACTAAGAAG
CCCTTCACTGCCAT-3′ (F), 5′- GACTGCGCCTGGTA
GTTGTT-3′ (R); GAPDH, 5′-GTGAAGGTCGGAGT
CAACG-3′ (F), 5′-GAAGATGGTGATGGGATTTCC-
3′(R); HPRT1, 5′-ACCCCACGAAGTGTTGGATA-3′ (F),




The statistical analyses were performed using the Statistical
Program for Social Sciences version 11.5 (SPSS Inc., Chicago,
IL, USA). Experiments were carried out in duplicate and data
are presented as means ± SD of at least five independent ex-
periments. Shapiro-Wilk and Kolmogorov-Smirnov normal-
ity tests were used to evaluate whether the data followed
normal distribution. Quantitative data were tested using
one-way analysis of variance (ANOVA) followed by Bonfer-
roni’s multiple comparison test or Kruskal-Wallis followed
by Dunn’s multiple comparison test, depending on whether
the data were parametric or nonparametric, respectively. The
level of significance was set to p < 0.05.
Results
Inflammatory factors secreted by macrophages affect
MSC morphology, adhesion, and migration
MSC were treated with CM from MΦGM or MΦM acti-
vated or not with LPS to examine the effects of inflamma-
tory cytokines on MSC (Fig. 1a). First, we determined the
concentrations in CM of some inflammatory factors
whose levels are known to change during the inflamma-
tory response subsequent to bone injury. CMGM+ con-
tained higher levels of the classical pro-inflammatory
cytokines TNF-α, IL-6, and IL-1β and lower levels of the
anti-inflammatory cytokine IL-10 than CMM+ (Table 1).
Moreover, the levels of the inflammatory chemokines IL-8
and MCP-1 were higher in CMGM+ than in CMM+. In
contrast, IL-10 and IL-1β levels could not be detected in
CM from non-activated MΦGM or MΦM, which contained
low concentrations of TNF-α, IL-6, IL-8, and MCP-1
(Table 1). MSC treated for 48 h with CM from activated
macrophages displayed a much more elongated morph-
ology than untreated MSC (Fig. 1b, c). Cell elongation was
more pronounced after treatment with CMGM+ than with
CMM+ (Fig. 1c). The organization of actin cytoskeleton,
involved in the acquisition of cell shape, showed
Table 1 Levels of inflammatory cytokines in conditioned medium from macrophages
TNF-α IL-6 IL-1β IL-10 IL-8 MCP-1
CMGM− (5.81 ± 1.11) × 10
−3 0.15 ± 0.02 N.D. N.D. 0.10 ± 0.02 1.13 ± 0.19
CMGM+ 14.16 ± 3.92 11.52 ± 2.85 0.12 ± 0.02 0.16 ± 0.03 5.22 ± 1.57 28.07 ± 4.02
CMM− (5.89 ± 1.32) × 10
−3 0.12 ± 0.03 N.D. N.D. 0.03 ± 0.01 1.18 ± 0.37
CMM+ 2.40 ± 0.40 2.10 ± 0.59 0.03 ± 0.01 2.58 ± 0.48 1.39 ± 0.32 11.05 ± 2.91
Conditioned medium (CM) was collected from MΦGM and MΦM treated (CMGM+ and CMM+, respectively) or not (CMGM− and CMM−, respectively) with 10 ng/ml LPS
for 90 min and incubated 5 h in fresh medium. The data are expressed as ng/ml of culture medium. N.D. not detected
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differences in untreated and treated MSC. Actin bundles
of MSC treated with CMGM+ or CMM+ organized in
closely packed parallel arrays throughout the stretched cell
body whereas actin filaments of untreated MSC were
more loosely spaced (Fig. 1b). No differences in cell shape
and elongation or in actin arrangement were found be-
tween MSC treated with CM from non-activated macro-
phages and untreated cells (Fig. 1b, c). To assess whether
exposure to CM affects MSC attachment, cells were
seeded on tissue culture plastic and subsequent cultured
up to 3 h. Attachment of MSC untreated and treated with
CM from non-activated macrophages was similar (Fig. 2a).
In contrast, the treatment of MSC with CM from acti-
vated macrophages increased cell attachment at all evalu-
ated time points. The number of attached cells was higher
when MSC were treated with CMGM+ than with CMM+.
Viability of MSC incubated in growth medium up to 14
days was unaffected by CM treatment (Fig. 2b) Next, we
determined whether factors secreted from macrophages
regulate MSC migratory activity. Treatment with CM
from activated macrophages increased MSC migration,
being this effect higher in MSC treated with CMGM+ than
with CMM+ (Fig. 2c). No effect on migratory activity was
observed in cells treated with CM from non-activated
macrophages. Together, these data indicate that CM from
activated macrophages, which contains high levels of in-
flammatory mediators, promotes MSC elongation, and en-
hances MSC ability to attach and migrate. These effects
were more noticeable when MSC were treated with
CMGM+ than with CMM+.
Inflammatory factors secreted by anti-inflammatory
macrophages enhance MSC osteogenic potential
Next, the effect of inflammatory factors secreted by
MΦGM or MΦM on MSC osteogenic differentiation was
investigated. We performed time-course experiments of
ALP activity in MSC treated with CM for 24–96 h and
further incubated in osteogenic media for 14 days. Treat-
ment of MSC for 24 h with CM from macrophages,
activated or not with LPS, did not lead to significant
changes in ALP activity (Additional file 1: Figure S1).
ALP activity was neither affected by the treatment of
MSC for 48 h with CM from non-activated macrophages
or with CMGM+ (Fig. 3a). However, MSC treated for 48
h with CMM+ showed increased ALP activity as
compared to untreated cells (Fig. 3a). Treatment of MSC
with CMM+ for 72 h also increased ALP activity, although
to a lesser extent than treatment for 48 h, whereas treat-
ment for 96 h had no effect (Additional file 1: Figure S1).
There was no alizarin red staining indicative of calcium
deposits in layers of MSC cultured in osteogenic medium
for 3–7 days (Additional file 1: Figure S2). Mineral de-
posits were visible in MSC layers after 14 days of incuba-
tion in osteogenic medium (Fig. 3b). As expected, alizarin
red staining was more intense in MSC incubated for 21
than for 14 days (Fig. 3b). At both time points, MSC
treated with CMM+ showed higher mineralization degree
than untreated cells (Fig. 3b).
We then determined whether treatment with inflam-
matory factors secreted by activated macrophages regu-
lates the expression, at the mRNA level, of osteogenic
markers in MSC. To this end, mRNA levels of RUNX2,
COL1A1, and ALPL were quantified in MSC treated with
CM for 48 h. Treatment of MSC with CM from non-
activated macrophages did not affect transcript levels of
any of the genes tested (Fig. 4a). However, MSC treated
with CMM+ showed higher RUNX2 mRNA levels than
untreated cells (Fig. 4a). Treating MSC with CMGM+ or
CMM+ led to a decrease in COL1A1 mRNA levels while
ALPL mRNA levels remained unaffected (Fig. 4a). Next,
we assessed whether treatment with CM modulates the
expression of RUNX2, COL1A1, and ALPL in MSC fur-
ther incubated in osteogenic medium. In general, the
culture of MSC, treated or not with CM, in media with
osteogenic inducers increased RUNX2 and ALPL mRNA
levels while decreased the levels of COL1A1 transcripts
(Fig. 4b). The expression of these genes in differentiating
MSC was not affected by treatment with CM from non-
activated macrophages (data not shown). In contrast,
RUNX2 mRNA levels in MSC treated with CMM+ were
higher than in untreated MSC at 3 days of differenti-
ation. At this time point, COL1A1 mRNA levels in MSC
treated with CMGM+ or CMM+ were lower than in un-
treated MSC. When incubation time extended to 7 or
14 days, there were no differences in RUNX2 or COL1A1
mRNA levels between MSC untreated and treated with
CM (Fig. 4b). Interestingly, after 7 days of incubation in
osteogenic medium, MSC treated with CMM+ but not
with CMGM+ showed higher ALPL mRNA levels than
untreated MSC, whereas no changes were detected
thereafter (Fig. 4b). Taking together, these results indi-
cate that the expression of RUNX2, ALPL, and COL1A1
in MSC is regulated by factors contained in CMM+, an
effect associated with increased osteogenic ability.
TNF-α and IL-10 secreted by anti-inflammatory
macrophages are involved in enhanced MSC osteogenesis
Treatment of MSC with CMM+, which contains higher
levels of IL-10 and lower levels of TNF-α than CMGM+,
enhanced their osteogenic potential. To investigate
whether MSC osteogenic differentiation is stimulated
by TNF-α and IL-10 secreted by MΦM, MSC were
treated for 48 h with CMM+ that had been incubated
with neutralizing TNF-α or IL-10 antibodies. Blocking
IL-10 but not TNF-α attenuated the increase in RUNX2
mRNA levels induced by treatment with CMM+
(Fig. 5a). Notably, COL1A1 mRNA levels in MSC
treated with CMM+ increased when TNF-α was blocked
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Fig. 2 Adhesion, viability and migration of MSC treated with CM. a Number of MSC treated or not (−) with CM from MΦGM and MΦM activated
(CMGM+ and CMM+, respectively) or not (CMGM− and CMM− , respectively) with LPS and further incubated in growth media (GrM) for the indicated
time points. b Viability of MSC treated or not with CM and further incubated in GrM for the indicated time points. The data are relative to those
measured in each group at day 1, which were given an arbitrary value of 100. c Migration capacity of MSC seeded inside the area confined by
squared silicone barriers, treated or not with CM and allowed to migrate for 5 days. Optical microscope images of cells stained with crystal violet.
*p < 0.05 between the indicated conditions
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whereas neutralization of IL-10 led to the opposite ef-
fect (Fig. 5a). ALPL mRNA levels in MSC, which
remained unaffected by treatment with CMM+, were re-
duced when TNF-α or IL-10 was neutralized (Fig. 5a).
Blocking TNF-α or IL-10 led to a decrease in ALP activity
of MSC treated with CMM+ and further incubated in
osteogenic medium (Fig. 5b). In contrast, the formation of
mineralized nodules by MSC treated with CMM+ de-
creased by blocking IL-10 but not TNF-α (Fig. 5c). It
should be noted that blocking TNF-α or IL-10 in CMGM+
had no effect on MSC osteogenesis (Additional file 1: Fig-
ure S3). These data indicate that TNF-α and IL-10 se-
creted by anti-inflammatory macrophages regulate MSC
osteogenic activity.
Fig. 3 Osteogenic activity of MSC treated with CM. a ALP activity in MSC treated or not (−) for 48 h with CM from MΦGM and MΦM activated
(CMGM+ and CMM+, respectively) or not (CMGM− and CMM− , respectively) with LPS and further incubated in osteogenic medium (OM) for 14 days.
b. Alizarin red staining and quantification in MSC treated or not with CM from macrophages and further incubated in OM for 14 days (upper
panel) or 21 days (lower panel). Data in b are relative to those measured in untreated MSC incubated in growth medium (GrM), which were given
an arbitrary value of 100. *p < 0.05 between the indicated conditions
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MSC response to treatment with TNF-α or IL-10
To further investigate the effect of TNF-α and IL-10 on
MSC osteogenesis, MSC were treated for 48 h with 0.1,
1, or 10 ng/ml TNF-α or IL-10 and mRNA levels of
RUNX2, COL1A1, and ALPL were quantified (Fig. 6a).
RUNX2 transcript levels increased only when MSC were
treated with 1 ng/ml IL-10. COL1A1 mRNA levels de-
creased after treating MSC with TNF-α at 1 or 10 ng/ml
while IL-10 had no effect at any tested dose. The effects
of IL-10 or TNF-α on ALPL expression were dependent
Fig. 4 Expression of bone-related genes in MSC treated with CM. a RUNX2, COL1A1, and ALPL mRNA levels in MSC treated or not (−) for 48 h with
CM from MΦGM and MΦM activated (CMGM+ and CMM+, respectively) or not (CMGM− and CMM−, respectively) with LPS. Data are relative to those
measured in untreated MSC, which were given an arbitrary value of 1. b RUNX2, COL1A1, and ALPL mRNA levels in MSC treated or not (−) for 48 h
with CMGM+ or CMM+ and further incubated in osteogenic medium (dark gray) for the indicated time points. Data are relative to those measured
in untreated MSC incubated in growth medium (light gray) for 3 days, which were given an arbitrary value of 1. *p < 0.05 between the
indicated conditions
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on the assayed dose. ALPL mRNA levels in MSC
remained unaffected by treatment with IL-10 at the low-
est dose while increased when IL-10 was applied at 1 or
10 ng/ml. TNF-α at 1 ng/ml also increased ALPL mRNA
levels in MSC whereas it had no effect at 0.1 or 10 ng/
ml. Treatment with TNF-α or IL-10 at 1 ng/ml increased
ALP activity of MSC incubated under osteogenic condi-
tions, which further increased by IL-10 at 10 ng/ml
(Fig. 6b). In addition, mineralized nodule formation in
MSC layers increased after treatment with 1 ng/ml TNF-
α and further increased with IL-10 at 1 or 10 ng/ml
(Fig. 6c). Treatment of MSC with IL-10 or TNF-α at the
lowest dose or with 10 ng/ml TNF-α had no effect on
MSC osteogenic differentiation (Fig. 6b, c). As incuba-
tion of MSC with CM from macrophages enhances
MSC adhesion and migration (Fig. 2a, c), we finally eval-
uated whether TNF-α and IL-10, at doses that enhance
osteogenesis, also modulate these processes. MSC
treated with cytokines displayed an elongated or irregu-
larly polygonal shape, similar to that observed in un-
treated cells (Fig. 7a). In fact, the average elongation
ratio of MSC untreated and treated with cytokines was
similar (Fig. 7b). MSC attachment was unaffected by
treatment with IL-10 at 10 ng/ml (Fig. 7c). In contrast,
MSC treated with TNF-α or IL-10 at 1 ng/ml attached at
a higher extent than untreated MSC (Fig. 7c). Treatment
with TNF-α and IL-10 did not affect MSC viability
(Fig. 7d). As observed for cell attachment, MSC migra-
tion increased upon treatment with TNF-α or IL-10 at 1
ng/ml (Fig. 7e). Together, these data indicate that treat-
ment with TNF-α and IL-10 at 1 ng/ml enhances MSC
adhesion, migration and osteogenesis.
Discussion
Macrophages play a key role during bone healing, participat-
ing in both initial inflammatory response and early anabolic
phase of repair [1]. Phenotypic switching of macrophages
during fracture healing leads to temporally controlled release
of inflammatory mediators [26]. While the prominent contri-
bution of inflammatory factors to fracture healing is well
established, their direct effects on osteogenic precursors are
not fully understood. Having recently shown that factors
Fig. 5 Involvement of TNF-α and IL-10 in the osteogenic activity of MSC treated with CM from anti-inflammatory macrophages. a RUNX2, COL1A1
and ALPL mRNA levels in MSC treated or not (−) for 48 h with CMM+ that had been incubated or not (−Ab) with TNF-α or IL-10 neutralizing
antibody (Ab). Data are relative to those measured in untreated MSC, which were given an arbitrary value of 1. ALP activity (b) and alizarin red
staining and quantification (c) in MSC treated or not with CMM+ and further incubated in osteogenic medium (OM) for 14 (b) or 21 (c) days. Data
in c are relative to those measured in untreated MSC incubated in growth medium (GrM), which were given an arbitrary value of 100. *p < 0.05
between the indicated conditions
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originated from pro-inflammatory and anti-inflammatory
macrophages enhance MSC immunoregulatory properties
[18], data herein provide evidence that MSC adhesion, mi-
gration, and osteogenic potential are also regulated by the in-
flammatory environment. Inflammatory cytokines influence
focal adhesion assembly and cytoskeleton rearrangement,
which regulate cell adhesion and migration [27, 28]. MSC
treated with CM from activated macrophages elongated as a
result of a more parallel arrangement of actin bundles. Cell
morphological elongation has been associated with an in-
creased migration rate [29]. In this regard, migratory activity
was higher in MSC treated with CMGM+ or CMM+ than with
CM from non-activated macrophages, supporting the in-
volvement of inflammatory cytokines in MSC mobilization.
In fact, treatment with TNF-α or IL-10 enhanced MSC abil-
ity to attach and migrate, although to a lesser extent than
CM from activated macrophages. Of note, CMGM+ increased
MSC elongation, attachment, and migration to a higher ex-
tent than CMM+, suggesting that pro-inflammatory factors
that participate in the early inflammatory response enhance
MSC mobilization to injured sites. It should be mentioned
that no obvious differences in cell elongation were noted be-
tween differentiating MSC treated with CM and untreated
MSC (Additional file 1: Figure S2), indicating that the effect
of CM on cell morphology was rapidly lost in osteogenic
medium.
The role of macrophage-derived factors in MSC osteo-
genesis remains controversial, mainly due to differences in
experimental setups used to study it [30]. Previous studies
have reported that the treatment of MSC with media con-
ditioned by pro-inflammatory macrophages increases
RUNX2 and ALPL mRNA levels [31] as well as cell layer
Fig. 6 Osteogenic activity of MSC treated with TNF-α or IL-10. a RUNX2, COL1A1 and ALPL mRNA levels in MSC treated or not (−) for 48 h with
TNF-α or IL-10 at 0.1, 1, or 10 ng/ml. Data are relative to those measured in untreated MSC, which were given an arbitrary value of 1. ALP activity
(b) and alizarin red staining and quantification (c) in MSC treated or not with TNF-α or IL-10 and further incubated in osteogenic medium (OM)
for 14 (b) or 21 (c) days. Data in c are relative to those measured in untreated MSC incubated in growth medium (GrM), which were given an
arbitrary value of 100. *p < 0.05 between the indicated conditions
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mineralization [32]. However, we found that the treatment
of MSC with CMGM+ did not result in increased MSC
osteogenic differentiation. A plausible explanation for this
discrepancy is that MSC osteogenesis was conducted in our
experiments in the absence of LPS whereas the previous
studies used CM containing LPS as stimulus. LPS regulates
MSC osteogenic differentiation, as treatment of MSC with
TNF-α plus LPS, but not with TNF-α only, enhanced ALP
activity and cell layer mineralization [22]. Unlike M1-like
phenotype, murine bone marrow macrophages [33] and
THP-1 cells [34] polarized to an M2-like phenotype release
factors that enhance MSC osteogenic differentiation, as ob-
served in co-cultures that allow the exchange of soluble fac-
tors without direct cell contact. In line with these data, we
observed enhanced ALP activity in MSC treated with fac-
tors secreted by human anti-inflammatory macrophages at
14 days of differentiation. Enhanced mineralized nodule for-
mation was also detected at this time, indicating earlier cal-
cium deposition to the matrix in MSC after exposure to
CMM+. Therefore, factors secreted by pro-resolving macro-
phages during the resolution of inflammation might con-
tribute to create a more favorable environment for MSC
osteogenesis than those released by pro-inflammatory mac-
rophages at the early stage of inflammation.
Inflammatory cytokines secreted by macrophages con-
tribute to bone formation, as injection of low-doses of
TNF-α at the fracture site accelerated bone healing in
mice [19]. Investigations into the role of TNF-α on
Fig. 7 Morphology, adhesion, viability, and migration of MSC treated with TNF-α or IL-10. a Optical microscope images showing the morphology
of MSC treated or not (−) for 48 h with the indicated doses of TNF-α or IL-10, after crystal violet staining. b Ratio of cell length to width as a
measure of cell elongation. c Number of MSC treated or not with TNF-α or IL-10 and incubated in growth medium (GrM) for the indicated time
points. d Viability of MSC treated or not with TNF-α or IL-10 and further incubated in GrM for the indicated time points. The data are relative to
those measured in each group on day 1, which were given an arbitrary value of 100. e Migration capacity of MSC seeded inside the area
confined by squared silicone barriers, treated or not with TNF-α or IL-10 and allowed to migrate for 5 days. Optical microscope images of cells
stained with crystal violet. *p < 0.05 between the indicated conditions
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osteogenic differentiation of stromal cells have been
mainly conducted using recombinant proteins. In the
present study, we show that TNF-α produced by macro-
phages regulates MSC osteogenic potential. Culture of
MSC with CMM+ incubated with a blocking anti-TNF-α
antibody attenuated the initial phase of osteogenesis, as
ALP induction was partially inhibited, whereas blocking
TNF-α in CMGM+ did not affect MSC osteogenic ability.
These data suggest that TNF-α may exert osteogenic ef-
fects at the onset of the resolution, when its levels start
to decrease. Interestingly, exposure of MSC to 1 ng/ml
TNF-α increased ALP activity whereas 10 ng/ml TNF-α
had no effect on MSC osteogenic differentiation. It is
worth mentioning that 1 ng/ml TNF-α is actually close
to the mean concentration, of about 700 pg/ml, detected
in serum samples from fracture hematomas of patients
within 72 h post-injury [35].
The influence of pro-resolving mediators on MSC osteo-
genesis remains poorly understood. Phenotypic switching of
macrophages during fracture repair leads to the production
of IL-10, found in serum samples from fracture hematomas
of patients at concentrations around 1 ng/ml [36]. A recent
study showed that recombinant IL-10 can enhance MSC
osteogenesis via the p38/mitogen-activated protein kinase
(MAPK) signaling pathway [25]. To our knowledge, our
study is the first to demonstrate that IL-10 secreted by mac-
rophages regulates MSC osteogenic differentiation. CMGM+
contained very low levels of IL-10, which had no effect on
MSC osteogenesis. However, significant IL-10 levels secreted
by anti-inflammatory macrophages enhanced MSC osteo-
genic ability, as blocking IL-10 led to a reduction in ALP ac-
tivity and mineralization in MSC treated with CMM+.
Experiments in which MSC were treated with recombinant
cytokines revealed that IL-10 was indeed more effective in
promoting matrix mineralization than TNF-α. In addition to
promote MSC osteogenesis, IL-10 enhanced MSC attach-
ment and migration at a dose of 1 ng/ml but not at 10 ng/
ml, suggesting that MSC functions could be tightly regulated
by anti-inflammatory mediators in the resolution of inflam-
mation. It should be noted that the effects of TNF-α and IL-
10 on in vitro MSC osteogenesis likely depend on the length
of their application, being pro-osteogenic after short-term
treatment, as in the present study, or inhibitory after con-
tinuous exposure [23, 25]. Based on our observations, we
speculate that the controlled release of inflammatory signals
by macrophages after injury could promote MSC osteogen-
esis. However, exacerbated and/or sustained pro-
inflammatory response could lead to chronic inflammation
and tissue destruction whereas excessive anti-inflammatory
macrophage activation could promote fibrosis and abnormal
extracellular matrix deposition.
Our data support the involvement of RUNX2 in early stages
of osteogenesis, as incubation of MSC in osteogenic medium
for 3 days increased RUNX2 mRNA levels. A recent study
showed that, in the absence of classic osteogenic inducers,
treatment of mouse mesenchymal precursors with cytokines
like IL-13 or IL-17A increased the expression of RUNX2, at
the protein level, and induced osteoblast differentiation [37].
Our data support the role of cytokines in regulating RUNX2,
as treatment of MSC with CMM+ for 48 h increased RUNX2
mRNA levels, an effect partially mediated by IL-10. MSC
treated with recombinant IL-10 at 1 ng/ml showed higher
RUNX2mRNA levels than untreated cells, supporting the role
of IL-10 in promoting MSC osteogenesis. No significant
changes in ALPL expression were observed in MSC immedi-
ately after treatment with CMM+. However, exposure to fac-
tors released by anti-inflammatory macrophages enhanced
ALPL expression in early differentiating MSC, as MSC treated
with CMM+ and incubated in osteogenic media for 7 days
showed higher ALPL mRNA levels than untreated cells.
COL1A1 is related to the proliferation period and its expres-
sion decreases when differentiation starts. mRNA levels of
COL1A1, which contains RUNX2 binding sites in its promoter
[38], decreased after treating MSC with CMM+, suggesting fur-
ther layers of transcriptional regulation. In this regard, TNF-α
is known to reduce collagen type I expression [39]. In fact, the
culture of MSC with CMM+ incubated with anti-TNF-α in-
creased COL1A1 mRNA levels and treatment of MSC with
TNF-α at 1 or 10 ng/ml decreased COL1A1 expression. Inter-
estingly, COL1A1 mRNA levels in MSC treated with CMM+
decreased when IL-10 was blocked, indicating that IL-10 and
TNF-α in CMM+ have opposite effects on COL1A1 expres-
sion. These results suggest that a correct balance between
pro- and anti-inflammatory cytokines is necessary for success-
ful collagen matrix deposition after bone injury. Of note, treat-
ment of MSC with IL-10 only did not alter COL1A1 mRNA
levels at any tested dose, which indicated that other factors se-
creted by anti-inflammatory macrophages cooperate with IL-
10 in the regulation of COL1A1 expression.
In summary, data in this study support the hypothesis that
inflammatory environment promotes MSC osteogenesis at
the onset of resolution rather than at the early stage of in-
flammation, which is more favorable for MSC recruitment.
We have demonstrated that IL-10 secreted by anti-
inflammatory macrophages potentiates MSC osteogenesis
by increasing the initial phase of matrix maturation as well
as mineralization. In addition, IL-10 enhances MSC ability
to attach and migrate, which in turn may contribute to
bone formation. It should be noted that, in addition to
TNF-α and IL-10, CM may contain a large range of sol-
uble factors that could contribute to regulate MSC osteo-
genesis. Current efforts to augment bone repair involve
the use of cytokines for local administration at the fracture
site or for priming protocols before MSC implantation
[40, 41]. Data herein provide new insights into how cyto-
kines in different inflammatory environments modulate
MSC osteogenesis, which may be helpful to develop ef-
fective bone regeneration strategies.
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Conclusions
Factors secreted by pro-inflammatory or anti-inflammatory
macrophages increased MSC attachment and migration.
These effects were more pronounced when MSC were
treated with media from pro-inflammatory macrophages.
MSC osteogenic activity was enhanced by factors released by
anti-inflammatory macrophages, but not by pro-
inflammatory macrophages. We found that IL-10 originated
from anti-inflammatory macrophages increased MSC osteo-
genic differentiation and regulated the expression of osteo-
genic markers. In addition, IL-10 potentiated the MSC
ability to attach and migrate. These findings contribute to
the understanding of the mechanisms by which phenotypic
switching of macrophages during bone repair influences
MSC osteogenesis and migration.
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Additional file 1: Figure S1. ALP activity in MSC treated for 24, 72 or
96 h with CM from MΦGM and MΦM activated (CMGM+ and CMM+,
respectively) or not (CMGM- and CMM-, respectively) with LPS and
further incubated in osteogenic medium (OM) for 14 days. Untreated
MSC (−) were incubated in growth medium (GrM) or OM for 14 days.
*p < 0.05 between the indicated conditions. Figure S2. Alizarin Red S
staining in MSC treated with CM from MΦGM and MΦM activated
(CMGM+ and CMM+, respectively) or not (CMGM- and CMM-,
respectively) with LPS and further incubated in osteogenic medium (OM)
for 3 or 7 days. Untreated MSC (−) were incubated in growth medium
(GrM) or OM for 3 or 7 days. Figure S3. Involvement of TNF-α and IL-10
in the osteogenic activity of MSC treated with CM from pro-inflammatory
macrophages. MSC were treated or not (−) for 48 h with CMGM+ that
had been incubated or not (−Ab) with TNF-α or IL-10 neutralizing anti-
body (Ab). ALP activity (a) and alizarin Red S staining and quantification
(b) in MSC treated or not with CMGM+ and further incubated in OM for
14 (a) or 21 (b) days. Data in b are relative to those measured in un-
treated MSC incubated in growth medium (GrM), which were given an
arbitrary value of 100.
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